DARE - Latest News

Daré Bioscience, Inc. (DARE), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $22.2M. Beta to the broader market is 1.09.

The article list below shows the most recent DARE headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent DARE Headlines

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

globenewswire.com - May 26, 2026

Receipt of award notice for second $1. 0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

globenewswire.com - May 18, 2026

Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV d

Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript

seekingalpha.com - May 14, 2026

Daré Bioscience, Inc.

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

globenewswire.com - May 14, 2026

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencemen

Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?

benzinga.com - May 12, 2026

Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is reporting positive interim results from its Phase 3 cli

How News Affects DARE Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track DARE's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked DARE news questions

What is the latest DARE news headline?

The most recent DARE headline (May 26, 2026) is "Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the DARE news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What DARE news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual DARE options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.